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2 0 1 8  A N N U A L  R E P O R T
I am pleased to present you with the 2018 Annual Report 
from The Jackson Laboratory (JAX), which highlights some 
of the major events and accomplishments of the year.
Undoubtedly the biggest highlight of the year was the 
opening of the Charles E. Hewett Center in Ellsworth. This 
state-of-the-art vivarium, named in honor of our recently 
retired executive vice president and chief operating officer, 
significantly expands JAX’s capacity for producing the mouse 
models of human health for which we are best known.  
JAX’s growth in 2018 was not confined to Maine. Our 
Farmington, Conn. campus has grown rapidly since the 
building opened in 2014 and thanks to surpassing targets for 
employment, grant funding, and other benchmarks of success, 
in 2018 the state of Connecticut announced forgiveness of the 
loans that helped launch our genomic medicine campus.
Our strong financial performance enabled us to continue 
investing in innovative science, particularly important with 
a large number of junior faculty at both our Bar Harbor and 
Farmington campuses. Seed funding — supported by operating 
surplus reinvested into our mission and by philanthropy — plays 
a vital role in launching new faculty research programs and 
positioning them to be competitive for larger federal grants.
The Laboratory’s eighth endowed faculty chair was established 
in 2018 through a generous gift from the Diana Davis Spencer 
Foundation. Associate Professor Gareth Howell, Ph.D., whose 
research focuses on neurodegeneration in glaucoma, Alzheimer’s 
disease and other conditions, was appointed as the inaugural 
Diana Davis Spencer Foundation Chair for Glaucoma Research.  
As always, JAX derives its strength from our talented and 
dedicated staff, from the innovative science conducted on our 
campuses, from our mice and the unique role we play in the 
global scientific community, and from the generous support 
of friends who share our vision for a healthier future.  
Thank you for helping us make 2018 a landmark year of 
growth and discovery for the Laboratory. With your support, 
we will achieve even greater things in the years ahead.
Warm regards,
Edison T. Liu, M.D. 
President and CEO
The Jackson Laboratory’s 
purposes are scientific, 
medical and educational. Our 
mission is to discover precise 
genomic solutions for disease and 
empower the global biomedical 
community in our shared quest 
to improve human health.
Get the latest news and insights. 
Visit www.jax.org/news.
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JAX SCHOLARSHIPS
Many promising students 
are unable to pursue higher 
education on account of the 
financial burden a college 
education presents. The JAX 
College Scholarship Program 
awarded a $10,000 scholarship 
to three students from 
under served backgrounds 
who will pursue a college 
degree and aspire to a 
career in biomedicine.
This annual program is 
open to graduating high 
school seniors who live in 
Connecticut or Maine, or in 
Sacramento County, Calif. One 
student from each location 
is awarded this scholarship.
SUPPORTING 
STEM INITIATIVES
The 72nd annual Maine State 
Science Fair, organized by 
The Jackson Laboratory and Maine 
Mathematics and Science Alliance, 
took place in March and included 
hundreds of students from across 
Maine. High school students 
competed for coveted state titles 
and more than $500,000 in 
scholarships and awards.
The Jackson Laboratory 
hosted three STEM (science, 
technology, engineering 
and math) open house 
events, one in Maine and 
two in Connecticut. These 
events brought hundreds of 
science-interested high school 
students and their parents and 
teachers to our campuses.
Current high school and 
undergraduate interns at JAX 
presented research that they 
have been conducting over 
the course of the academic 
year. Attendees also heard 
from JAX scientists who gave 
talks about their research 




The Jackson Laboratory was 
the featured collaborator of 
a 2018 Bark for Life event in 
Connecticut. Bark for Life is 
an American Cancer Society 
event that honors the 
caregiving qualities of our 
canine family while raising 
money for lifesaving cancer 
research, advocacy, education 
and patient service programs. 
Bark for Life celebrates the 
unique and healing bond 
between humans and their 
dogs, while contributing 
to the fight against cancer. 
A JAX team showed attendees 
how canines are helping 
to cure cancer through our 
Tallwood Cancer Canine 
Research Initiative.
TACKLING ALZHEIMER’S
Alzheimer’s disease is a debilitating, 
degenerative brain disease, causing 
short-term memory loss and, as 
it progresses, motor function and 
long-term memory loss. In February, 
The Jackson Laboratory and the 
Alzheimer’s Association, Maine Chapter 
co-hosted a discussion about the complexities 
of Alzheimer’s disease, to share the latest research 
and bring together a community of scientists and those 
whose lives are affected by Alzheimer’s. The event 
included U.S. Senator Susan Collins (R-ME).
JAX sponsored the 21st Annual Dementia Education 
Conference organized by the Connecticut Chapter of 
the Alzheimer’s Association in April at Mohegan Sun. 
JAX Alzheimer’s researchers presented “Genetics, 
Environment and Alzheimer’s Disease Susceptibility” 
to more than 1,000 attendees, where they discussed 
how behaviors and genetic differences affect the 
brain and may contribute to Alzheimer’s onset as 
well as what they reveal about disease pathways.  
In collaboration with the Alzheimer’s Association 
Maine, Connecticut and Northern California 
chapters, the JAX team is building upon its promising 
research to reach another population impacted 
by Alzheimer’s disease: caregivers. In April, more 
than 100 JAX employees volunteered to complete 
projects to help families impacted by Alzheimer’s 
disease in Maine, Connecticut and California. 
In Maine, 60 volunteers created care packages to help 
make Alzheimer’s caregivers — who often spend much 
of their daily lives focused on helping their family 
members — feel pampered. Volunteers also helped 
with spring cleanup projects in Bangor and Ellsworth.
In Connecticut and California, 34 volunteers and 
36 volunteers, respectively, spearheaded statewide 
spring cleanups for caregiver families. They raked yards, 
prepared soil for spring gardens, cleaned windows 
and did a variety of other outdoor chores, allowing 
caregivers to take these tasks off their “to do” lists.
U.S. Senator Angus King (D-ME) hosted a 
round-table discussion about Alzheimer’s 
disease, which included JAX researchers 
Catherine Kaczorowski, Ph.D., and Greg Carter, Ph.D., 
along with the chief of neuropsychiatry at Acadia 
Hospital and Northern Light Eastern Maine 
Medical Center, and the executive director of the 
Maine Chapter of the Alzheimer’s Association. 
In June, a team of 36 JAX employees donned 
purple shirts and visited Bar Harbor’s downtown 
restaurants, stores and businesses to kick off an 
initiative to help make the island dementia-friendly. 
The project was part of the Alzheimer’s Association’s 
The Longest Day® event to help raise awareness for 
Alzheimer’s care and support, and advance research.
The team worked to help educate restaurant and store 
owners and staff about Alzheimer’s. They hope to 
ensure people with dementia can live independently 
for as long as possible and are able to engage 
in a variety of activities in their home towns.
COMMUNITY  
    INITIATIVES
JAX volunteers from Sacramento helping a family 
living with Alzheimer’s disease clean up their yard.
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INTRODUCING THE CHARLES E. HEWETT CENTER
In August, The Jackson Laboratory celebrated the ribbon 
cutting of its state-of-the-art vivarium in Ellsworth, Maine, 
which will enable wider access to vital JAX mouse resources 
for the worldwide biomedical research community. The 
Charles E. Hewett Center represents the culmination of 
nine decades of unmatched experience and leadership 
in breeding and caring for laboratory mice. 
The center is named in honor of The Jackson Laboratory’s 
transformational former Executive Vice President and 
Chief Operating Officer Charles E. Hewett, Ph.D. Hewett’s 
accomplishments included launching numerous research 
products and services; completing new research 
laboratories in Bar Harbor; expanding and relocating 
the Laboratory’s California operations; conceiving and 
leading the development of The Jackson Laboratory for 
Genomic Medicine in Farmington, Conn.; and establishing the 
vision for the new mouse production facility in Ellsworth. 
Hewett has been a strong champion for JAX employees 
and has also worked tirelessly for their fitness and health, 
outstanding benefits, and competitive salaries and wages.
“We are proud to be headquartered in Maine, where we 
are one of our state’s largest private employers, bringing 
in more than $800 million in economic activity each year 
and providing more than 2,200 jobs,” Hewett says. “We 
look forward to partnering with the Ellsworth community 
to advance vital biomedical research around the world.” 
THE JACKSON LABORATORY FOR GENOMIC MEDICINE: 
FIVE YEARS, TENFOLD GROWTH
When JAX broke ground on its new genomic medicine facility 
in Farmington, Conn., in 2013, there were only 30 employees. 
As of the end of 2018, The Jackson Laboratory for 
Genomic Medicine onboarded more than 350 researchers, 
technicians and staff from around Connecticut and the 
world. This includes 173 senior scientists with 26 faculty 
members leading research programs in cancer, genomic 
structure and regulation, human genetics, computational 
biology, gene editing, immunology, human microbiome, 
cellular engineering, and infectious disease. Some of 
the new top scientists were recruited with UConn Health 
and Connecticut Children’s Medical Center, which further 
strengthens our ties with key regional collaborators. 
This significant growth and the more than $70 million in 
external research grants awarded since the opening of the 
Farmington facility are clear measures of JAX’s success.
The vision for creating JAX’s genomic medicine campus, 
built upon JAX’s mammalian genetics expertise to 
discover the precise genomic causes of human disease 
and develop individualized diagnostics, treatments 
and cures, has been truly transformational. 
“In just five years, The Jackson Laboratory for 
Genomic Medicine has become a scientific powerhouse,” 
said the facility’s scientific director, Professor 
Charles Lee, Ph.D., FACMG. “We’re proud that top 
scientists from all over the globe are coming to JAX 
and joining our quest to improve human health.” 
GROWTH   
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To date, most mice used for Alzheimer’s research have been 
maintained on one or few genetic backgrounds. But humans don’t 
possess such genetic consistency, and using these single inbred 
mouse strains has notable limitations for such a genetically complex 
disease. In her lab, Associate Professor Catherine Kaczorowski, Ph.D., 
has generated and characterized a panel of mice with diverse genetic 
backgrounds that recapitulates the human disease spectrum to 
provide a better platform for translating research findings to the clinic.
Kaczorowski and her team worked to develop a mouse population that 
models human Alzheimer’s disease as well as human genetic diversity 
at the same time. The result, as published in Neuron, is a new mouse 
panel called AD-BXDs. These mice harbor the identical high-risk 
Alzheimer’s disease mutations found in human genes, but have highly 
variable genetic contributions across the remainder of the genome. 
“The ultimate goal of our Alzheimer’s disease research is to translate 
our findings into viable human therapeutics or biomarkers of 
disease,” says Kaczorowski. “The AD-BXD panel is an important 
step toward doing just that. It may provide the experimental 
platform we need to identify, for the first time, important 
genetic modifiers of Alzheimer’s disease susceptibility. These, 
in turn, can be targeted as new therapeutic opportunities.”
The Neuron paper underscores how important genetic 
diversity can be for Alzheimer’s research. Future studies 
using the panel will identify genomic regions involved with 
regulating cognitive decline and search for specific genes 
that contribute to resilience in particular mouse strains.
The complexity and long progression of Alzheimer’s disease is 
very difficult to recreate in the laboratory. JAX is addressing 
the problem, using human patient data and genetic engineering 
methods to create more accurate animal models of disease. 
The MODEL-AD Center is an ambitious National Institute of 
Aging-funded project to develop and distribute precise mouse 
models of late-onset Alzheimer’s. In 2018, the Center released 
10 new models carrying genetic mutations found in patients. The 
animals are being made available immediately to the worldwide 
scientific community, to expedite new research efforts.  
In past decades, most Alzheimer’s researchers had to rely on 
mouse models that carried a genetic mutation associated with 
the relatively rare, early-onset, familial version of the disease. 
But at least 95 percent of the more than 5.4 million Alzheimer’s 
patients in the U.S. have the late-onset version of the disease, 
which has not yet been successfully modeled in mice.
The project’s leaders expect to create more than 40 new 
mouse models based on human data sets, screen more than 
24 models — including deep phenotyping of at least eight new 
models — and establish a preclinical testing pipeline. 
“CRISPR/Cas9 technology enables us to quickly create new 
mouse models with precise genetic mutations — even multiple 
mutations in a single mouse,” says JAX Research Scientist 
Michael Sasner, Ph.D. “And we now have a wide range of -omics, 
biomarker and imaging technologies to evaluate how well a 
given mouse models late-onset Alzheimer’s disease.”
A BETTER MOUSE MODEL 
FOR ALZHEIMER’S RESEARCH
BUILDING A PRECLINICAL 
TESTING PIPELINE
RESEARCH   
    HIGHLIGHTS
Gareth Howell, Ph.D.
“I’m proud of the groundbreaking 
research my colleagues and I are 
doing at JAX, and I’m also proud to 
see our labs join forces to improve 
the quality of life for people with 
Alzheimer’s and their caregivers today.”
Catherine Kaczorowski, Ph.D.
“Our lab is focused on synergizing 
mouse and human genomics 
so we can translate results 
effectively. We need mice to get 
drug targets and to test causality.”
Mike Sasner, Ph.D., research scientist (left),  
and Greg Carter, Ph.D., associate professor (right).
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Members of the Verhaak Lab attend a lab meeting.
TARGETING ADVANCED 
BREAST CANCERS
Glioblastoma is the most common and 
aggressive form of brain cancer, and it quickly 
becomes resistant to standard therapies. New 
research is providing a better understanding of 
the processes underlying cell-to-cell differences 
within these tumors — a crucial finding because 
the differences contribute to therapy resistance.
Professor Roel Verhaak, Ph.D., is researching 
these mechanisms of resistance, and he’s 
discovered that an important clue lies outside of 
the regular genomic sequence. Gliomablastoma 
cells often contain additional DNA, called 
extrachromosomal DNA (ecDNA), that provide 
an added mechanism for therapy resistance. 
The ultimate goal is to identify what pathways 
can be targeted to block glioma progression.
In a recent paper in Nature Genetics, the 
team reports that tumor progression is often 
driven by cancer-promoting genes, known as 
oncogenes, on extrachromosomal pieces of 
DNA. First observed under microscopes in 
cancer cells more than 50 years ago, ecDNA 
has been relatively ignored because it’s hard 
to detect using standard sequencing methods, 
which don’t accurately detect and separate it 
from chromosomal DNA. But it’s now attracting 
more attention, and the work moving forward 
may help explain why cancers are difficult to 
treat and evolve therapy resistance so rapidly.
“We think targeting ecDNA has huge potential 
for the development of new cancer treatments,” 
says Verhaak. “We’re now working to develop 
sequencing-based protocols to identify ecDNA 
more efficiently. The bigger goal is to learn 
how and why ecDNA elements form. If we 
can block those mechanisms, we’ll have a 
way to prevent the evolution, and perhaps 
even the formation, of many cancers.”
DISRUPTING CANCER EVOLUTION
RESEARCH   
    HIGHLIGHTS
Karolina Palucka, M.D., Ph.D.
“It’s an exciting time to be involved 
in immunotherapy research. 
My research program in cancer 
immunology is thriving, thanks to 
collaborations with my colleagues 
at JAX and our state-of-the-art 
facilities in Connecticut.”
Some cancers are associated with inflammation. 
Professor Karolina Palucka, M.D., Ph.D., and 
colleagues have found a new immune signature 
in breast cancers that drives inflammation 
and corresponds with poor clinical outcomes. 
Known as the IL1 signature, the research team 
demonstrated it can be effectively targeted 
using an existing autoimmune therapy.
Palucka collaborated with researchers 
at The Baylor Institute for Immunology 
Research to show that IL1b, a member of the 
interleukin 1 family of cytokines (proteins 
released by certain cells of the immune 
system), drives the inflammation often found 
in cancer. In women with HER2-negative 
metastatic breast cancer, it can appear as an 
“IL1 signature.” The team’s report appeared as 
the cover article in the journal Cancer Research.
“We found that IL1b orchestrates 
tumor-promoting inflammation in breast 
cancer,” Palucka says, “and its presence 
corresponds with poor clinical outcomes. 
We show that it can be effectively targeted 
in patients using anakinra, a naturally 
occurring IL1 receptor antagonist.”
Anakinra is already widely used to treat 
autoimmune and autoinflammatory diseases 
and is being tested as an adjunct therapy to 
reduce the inflammation of metastatic cancer, 
including metastatic colorectal cancer. In the 
new study, women with advanced metastatic 
HER2-negative breast cancer received 
anakinra treatment, and, after just two weeks, 
showed reduced gene expression of IL1b and 
other cytokines and signaling pathways. 
The patients then received anakinra in 
combination with standard chemotherapeutics 
for HER2-negative cancers for a median 
duration of four months and some patients 
reported less pain and increased quality of 
life during this combination treatment.
Roel Verhaak, Ph.D.
“My laboratory is ideally situated 
to take advantage of the excellent 
technology and research service 
infrastructure at JAX. It’s a really 
good environment for research and 
I have wonderful colleagues here.”
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Our genomes may appear to be tidy, 
in theory. Humans share very similar 
genome sequences and most of us have two 
copies of each of 22 chromosomes, plus XX 
or XY sex chromosome combinations. In truth, 
however, genomes are somewhat messier.
Structural variants (SVs) in the genome — segments 
of DNA that are duplicated, deleted, inverted, 
inserted, translocated and more — are far more 
common than originally expected, even in outwardly 
healthy people. Indeed, on average they provide 
about five times more genetic variability among 
individuals than single nucleotide differences. 
And as we learn more about genomes, we’re 
finding out that SVs can also be important 
contributors to disease, including many cancers.
But SVs are very difficult to identify in 
high-throughput sequencing techniques, 
especially the most common method, which is 
short-read genome sequencing. While short-read 
sequencing is inexpensive and accurate, the process 
of assembling millions of short sequences into the 
whole genome leaves gaps that miss many SVs. The 
result is an incomplete picture of genomic variation 
and failure to detect SVs that may cause disease. 
To address the problem, researchers in the laboratory 
of Professor Charles Lee, Ph.D., FACMG, have 
constructed a new SV identification tool, FusorSV, 
which combines eight existing calling methods 
(e.g., sequence data variant identification) with a 
new algorithm, that was built using 27 genomes 
that have undergone deep coverage from the 
1000 Genomes Project. In a paper published in 
Genome Biology, the researchers present their data 
mining approach to assessing algorithm performance 
and merging the output from the existing calling tools. 
The result is a more sensitive structural variant caller 
with increased accuracy, that yields more insight 
into the roles of SVs in healthy function and disease.
Type 2 diabetes is a rapidly growing 
health problem in the United States and 
around the world. It’s also one of the most 
complex diseases we face, with many 
significant risk factors, including being 
overweight and physically inactive. Family 
history is another risk factor, but finding 
genetic targets to develop effective and 
safe treatments has been challenging.
Insulin, produced in islet cells in the 
pancreas, is supposed to transport glucose 
into cells. In type 2 diabetes, the body 
loses the ability to use insulin as well as 
it should, or the islet cells can’t produce 
enough insulin. This leads to dangerously 
high levels of glucose in the blood.
JAX researcher Michael Stitzel, Ph.D., is 
using new research methodologies to 
uncover previously unknown genetic 
mechanisms of type 2 diabetes, opening 
new avenues for therapies. He is the senior 
author of a paper in The American Journal of 
Human Genetics that identifies new genetic 
clues to type 2 diabetes mechanisms. 
“We have linked DNA sequence changes 
associated with type 2 diabetes and islet 
dysfunction to a pathway modulating islet 
function and stress responses,” Stitzel 
says, “and we’ve identified two genes 
that could be new therapeutic targets.”  
Using advanced research methods at 
JAX, the research team was able to link a 
diabetes-associated DNA sequence variant 
to altered function of a molecular switch 
and faulty expression of the C2CD4B gene 
in pancreatic islets. The same variant may 
also cause defective expression of a second 
gene, C2CD4A. Both genes are activated in 
islets by stressors such as inflammatory 
cytokines and saturated fatty acids rapidly.
Stitzel’s latest discovery at the cellular 
level is just a piece of one larger 
targeted therapeutic approach.
“What we’re trying to achieve is a transition 
from ‘average’ understanding and standard 
therapeutic approaches to something 
more precise and targeted, wherein we 
stratify patients in order to understand: 
What is your particular genetic risk?”
NEW THERAPEUTIC TARGETS 
FOR TYPE 2 DIABETES
CALLING ALL STRUCTURAL VARIANTS
RESEARCH   
    HIGHLIGHTS
Michael Stitzel, Ph.D.
“Here at JAX, we can really leverage 
the genetic diversity in the mouse, and 
we can also ‘humanize’ regions of the 
genomic dark matter in the mouse.”
Charles Lee, Ph.D., FACMG
“I feel such positive energy 
from faculty and staff. It’s a 
privilege to have the opportunity 
to do something that goes 
far beyond ourselves — to 
contribute to breakthroughs 
that will benefit mankind.”
Scientists working in the Stitzel Lab at the Farmington facility.
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In 2018, Bangor Savings Bank 
pledged $100,000 toward 
the Charles E. Hewett, Ph.D., 
Leadership Excellence 
Fund. On Feb. 14, 2019, 
representatives from the 
bank visited the Laboratory’s 
Bar Harbor campus to 
present their gift. JAX and 
Bangor Savings Bank share 
many connections, including 
deep roots in Maine.
Thanks to the generosity of 1,895 donors, 
the participation of faculty and senior 
leadership, and the incredible research 
being conducted across the Laboratory, 
JAX raised a total of $9,469,303 in 2018, 
an increase of $1.9 million over 
fundraising results the previous year.   
JAX received nearly $3.3 million 
through estate planned gifts, with JAX’s 
recognition club for planned gifts, the 
Society for Discovery, welcoming 14 new 
members. Carolyn Hansen Montgomery is a 
member of the Society for Discovery and an 
alumna of the JAX Summer Student Program 
(class of 1955–56). “Now, 60-some-odd years 
later, I appreciate even more the unique 
opportunity to test my independent wings 
and what a research environment is really 
like,” said Carolyn, explaining her motivation 
to give back to the Laboratory. “I can also 
see where some of our rudimentary studies 
contributed to the evolution of in vitro 
fertilization and species preservation. I am 
committed to doing what I can to support 
educational programs at JAX so 17 year 
olds (and others) can enjoy the stimulation, 
encouragement and growth opportunities 
these research opportunities offer.”
More than $2.4 million was raised by the 
Laboratory’s annual giving program, the 
Helix Fund. Membership in the Helix Fund 
Signature Societies is at an all-time high, 
with more than 300 members in these 
special donor recognition societies. In 2018, 
The Laboratory also launched its first 
recognition society, the Catalyst Circle, for 
donors who make a recurring monthly gift. 
To learn more about the Helix Fund, planned 
giving, giving societies or how to contribute 
to the Laboratory, visit www.jax.org/give.
The Charles E. Hewett, Ph.D., Leadership 
Excellence Fund was established in August of 
2018 in honor of former Jackson Laboratory 
Executive Vice President and Chief Operating 
Officer Charles (Chuck) Hewett, Ph.D.
More than 30 inaugural donors 
helped The Jackson Laboratory raise 
nearly $1 million toward leadership 
development programs for laboratory 
employees in honor of Hewett.
The fund empowers the next generation 
of JAX leaders and will support 
educational opportunities, professional 
development, mentorship programs, 
and health and wellness initiatives. 
Hewett retired at the end of 2018 after 
15 years of service to the Laboratory. 
He currently serves on JAX’s Board of 
Trustees. JAX recently named its new 
vivarium facility in Ellsworth, Maine, 
in Hewett’s honor (see Page 6). 
The first gift that launched the fund came 
from the Johnson family, who have been 
loyal supporters of the Laboratory for 
20 years. E. Thomas (Tom) Johnson, Jr., 
his mother, Cynthia (Cindy) Johnson, and 
their family were the leaders in launching 
the fund with the initial gift of $300,000. 
“We were happy to contribute to a fund that 
fosters both leadership and wellbeing at 
the Laboratory,” says Tom Johnson. “Strong 
organizational leadership has always been 
important to our family, so it is an honor to 
give back to JAX for this purpose. Our gift 
was a very natural way to celebrate the 
special connection and great mutual respect 
that my father, Tom, and Chuck shared.”
Thomas C. Barry
Mark S. Blumenkranz, M.D.
Otis W. Brawley, M.D.
Kathleen A. Corbet
Louis J. D’Ambrosio
Timothy D. Dattels 
Julie H. Daum
David D. Elliman
Anthony B. Evnin, Ph.D.
Steven B. Fink, J.D.
Jeffrey M. Friedman, M.D., Ph.D.
Paul A. Godley, M.D., Ph.D., M.P.P., (dec.)
John A. Gibbons
Charles E. Hewett, Ph.D.
Jean Hoffman
Richard S. Lannamann
Edison T. Liu, M.D.
Neal B. Milch, J.D.
George G. Montgomery
Frank Moss, Ph.D.
Dennis J. Paustenbach, Ph.D.
Jenny E. Rooke, Ph.D.
Janet Rossant, Ph.D.
David J. Roux, chairman
Geoffrey W. Smith, J.D.
Joan A. Steitz, Ph.D.
Mary Kate Wold, J.D.
FUNDRAISING
DONORS LAUNCH EMPLOYEE LEADERSHIP 
FUND TO HONOR CHARLES E. HEWETT
2019 BOARD OF TRUSTEES
PHILANTHROPIC   
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Gareth Howell, Diana Davis Spencer Foundation 
































    FOR EXCELLENCE
In 2018, The Jackson Laboratory and 
the Diana Davis Spencer Foundation 
joined forces to combat a leading cause 
of blindness worldwide: glaucoma.
JAX received $1.5 million from the Foundation 
to establish the Diana Davis Spencer 
Foundation Chair for Glaucoma Research, 
which was matched with an additional 
$1.5 million from the Laboratory, authorized 
JAX Board of Trustees. The chair is held by 
neurobiologist Gareth Howell, Ph.D., who 
researches the fundamental processes 
in the onset of glaucoma and other 
age-related neurodegenerative diseases. 
Glaucoma causes a progressive, irreversible 
vision loss caused by damage to the 
retinal nerve cells. It is the leading cause 
of blindness worldwide, and is expected to 
affect 80 million people by the end of the 
decade. Howell has shown that glaucoma, 
like other neurodegenerative diseases, 
involves immune responses that contribute 
to the loss of nerve cells in the eye. A 
subset of these immune cells originates 
in the blood, so Howell and his colleagues 
are studying these particular cells to 
develop new treatments that target them.
Howell is the eighth JAX faculty member to 
hold an endowed chair at the Laboratory. 
These distinguished positions honor 
the work of outstanding faculty while 
providing invaluable support for use in 
research, teaching or service activities.
$1.5 MILLION GIFT FOR GLAUCOMA RESEARCH 
BY DIANA DAVIS SPENCER FOUNDATION


















STATEMENT OF FINANCIAL POSITION  ( IN  MILLIONS)   2 0 1 8  2 0 1 7
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Other Assets  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  24.7 24.5
Endowment Investments  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  261.9 167.7
Net Receivables   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  49.6 41.3
Total Assets  1,024.7 890.1
LI ABILITIES AND FUND BALANCES
Current Liabilities   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  71.3 81.6
Bonds Payable, Net   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  213.5 92.2
Connecticut Forgivable Loans at Fair Value  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  – 3.4
Net Assets  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  739.9 712.9
Total Liabilities and Net Assets  1,024.7 890.1
STATEMENT OF ACTIVITY  ( IN  MILLIONS)
OPERATING REVENUE
Government Support   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  86.8 79.7
Foundation and Other Grants  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  9.4 8.2
Philanthropic Gifts  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  4.3 3.5
Program Revenues  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  285.1 256.7
Investment Return  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  7.0 19.2
Other Revenue   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  2.2 3.7
Operating Revenue  394.8 371.0
OPERATING EXPENSES
Research   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  138.6 131.9
Program Expenses  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  173.6 155.8
Institutional Support  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  54.5 47.4
Operating Expenses  366.7 335.1
Increase in Net Assets from Operating Activities  28.1 35.9
NON-OPERATION FINANCIAL SUPPORT
Construction Grants  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  7.9 7.0
Contributions for Plant and Endowment   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  2.9 1.7
Long-Term Investment Return, Net of Amount Used  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  (21.2) 20.9
Realized and Unrealized Gain on Interest-Rate Swaps  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  0.6 1.2
Adjustment to Fair Value for Connecticut Forgivable Loans  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  8.7 13.1
Other   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  0.1 0.2
Increase (Decrease) in Net Assets from Non-Operating Activities  (1.0) 44.1
Increase (Decrease) in Net Assets  27.1 80.0
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The Jackson Laboratory is an independent, nonprofit biomedical 
research institution with more than 2,200 employees. Headquartered 
in Bar Harbor, Maine, it has a National Cancer Institute-designated 
Cancer Center, locations in Ellsworth, Maine, Sacramento, Calif., and 
Shanghai, China, and a genomic medicine institute in Farmington, Conn. 
To learn more, visit our website at www.jax.org and subscribe to our 
Leading the Search e-newsletter at www.jax.org/subscribe. Follow 
us on Twitter, Facebook, YouTube, LinkedIn and Instagram.
M A I N E  |  CO N N E CT I C U T  |  C A L I FO R N I A  |  S H A N G H A I
WE DISCOVER  PRECISE GENOMIC  
 SOLUTIONS FOR DISEASE  
 AND EMPOWER THE  GLOBAL BIOMEDICAL  
 COMMUNITY  IN OUR SHARED QUEST  
  TO IMPROVE  
   HUMAN HEALTH.
